Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor

International Journal of Hematology

Volumn 99, Issue 5, 2014, Pages 577-587

  Ogiwara, Kenichi ^a   Nogami, Keiji ^a   Matsumoto, Tomoko ^a   Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

aPCC; Hemophilia A; Inhibitor; TFPI; Thrombin generation

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; ALLOANTIBODY; ANTIIDIOTYPIC ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; MONOCLONAL ANTIBODY; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; THROMBOPLASTIN;

ADULT; ARTHROPATHY; ARTICLE; BLOOD CLOTTING; CASE REPORT; CHILD; DISEASE SEVERITY; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOSCOPIC SURGERY; FINE NEEDLE ASPIRATION BIOPSY; HEMARTHROSIS; HEMATOMA; HEMOPHILIA A; HUMAN; MALE; PRESCHOOL CHILD; SYNOVECTOMY; THERAPY EFFECT; TREATMENT RESPONSE; YOUNG ADULT; BLOOD; BLOOD CLOTTING TEST; COMPLICATION; HEMORRHAGE; IMMUNOLOGY; METABOLISM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CHILD, PRESCHOOL; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; ISOANTIBODIES; MALE; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; THROMBOPLASTIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901622557     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1572-4     Document Type: Article

References (22)

1. Lusher JM. The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors. Scand J Haematol. 1984;40:195-202. (Pubitemid 14097140)
2. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998;9:119-28. (Pubitemid 28216256)
3. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546-51. (Pubitemid 46105952)
4. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15:3-10.
5. Stenbjerg S, Jorgensen J. Resistance to activated FIX concentrate (FEIBA). Scand J Haematol. 1977;18:421-6. (Pubitemid 8120113)
6. Fukui H, Fujimura Y, Takahashi Y, Mikami S, Yoshioka A. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titer factor VIII inhibitor. Thromb Res. 1981;22:177-84. (Pubitemid 11034167)
7. Hayashi T, Tanaka I, Shima M, Yoshida K, Fukuda K, Sakurai Y, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia. 2004;10:397-400. (Pubitemid 39077041)
8. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry. 1981;20:833-40.
9. Nakahara Y, Miyata T, Hamuro T, Funatsu A, Miyagi M, Tsunasawa S, et al. Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese hamster ovary cells: one N-and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2. Biochemistry. 1996;35:6450-9.
10. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol. 1997;55:183-7. (Pubitemid 27360053)
11. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33:4-15. (Pubitemid 37449290)
12. Duckers C, Simioni P, Spiezia L, Radu C, Gavasso S, Rosing J, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112:3615-23.
13. Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol. 2009;90:576-82.
14. Luu H, Ewenstein B. FEIBA® safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004;10:10-6. (Pubitemid 40045405)
15. Maurissen LF, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost. 2010;8:750-8.
16. Mori Y, Hamuro T, Nakashima T, Hamamoto T, Natsuka S, Hase S, et al. Biochemical characterization of plasma-derived tissue factor pathway inhibitor: post-translational modification of free, full-length form with particular reference to the sugar chain. J Thromb Haemost. 2009;7:111-20.
17. Caprini JA, Traverso CI, Arcelus JI. Perspectives on thromboelastography. Semin Thromb Hemost. 1995;21:91-3. (Pubitemid 26015186)
18. Váradi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003;1:2374-80.
19. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233-42. (Pubitemid 351161194)
20. Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordøy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res. 1997;85(4):13-25.
21. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264:18832-7. (Pubitemid 19277636)
22. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol. 2006;124:747-57. (Pubitemid 44066599)